MapLight Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on discovering and developing therapies for central nervous system disorders. The company leverages a proprietary platform that integrates optogenetics, single-cell transcriptomics, and spatial transcriptomics to identify neural circuits linked to disease and to target those circuits with novel drug candidates. Its lead product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic designed to treat schizophrenia and Alzheimer's disease psychosis. Beyond the lead candidate, the pipeline includes ML-004, a serotonin 1B/1D agonist formulation of zolmitriptan for autism spectrum disorder; ML-009, a GPR52 positive allosteric modulator for hyperactivity and impulsivity disorders; ML-055, a next generation M1/M4 muscarinic agonist for neuropsychiatric conditions; and ML-021, an M4 antagonist for motor deficits in Parkinson's disease. The company aims to advance these candidates through clinical development to address significant unmet needs in neuropsychiatric care.

MapLight Therapeutics, Inc. has not yet generated product revenue because it remains in the clinical development stage and does not operate a commercial organization for sales or distribution. The company funds its research and development activities through equity offerings, private placements, and other financing transactions. It has incurred substantial expenses related to clinical trials, preclinical studies, and personnel as it advances its pipeline candidates. Upon potential regulatory approval, the company intends to establish internal commercial capabilities or partner with third parties to market and distribute its therapies.

Within the competitive landscape of central nervous system therapeutics, MapLight Therapeutics positions itself alongside established players such as Bristol Myers Squibb, which markets Cobenfy for schizophrenia, and AbbVie and Neurocrine Biosciences, which are advancing muscarinic targeted programs like emraclidine and direclidine. The company differentiates itself through its circuit based discovery platform that aims to improve efficacy, safety, and tolerability compared with existing dopaminergic antipsychotics that primarily target dopamine D2 receptors and are associated with side effects such as extrapyramidal symptoms, metabolic changes, and hyperprolactinemia. Its pipeline includes multiple candidates targeting diverse indications such as autism spectrum disorder, hyperactivity disorders, and Parkinson's disease, providing breadth beyond many single focus competitors. This approach seeks to address unmet needs in symptom domains that current therapies often fail to treat adequately, including negative and cognitive symptoms of schizophrenia and psychosis in Alzheimer's disease. Additionally, the company’s focus on synchronizing pharmacokinetic profiles of agonist and antagonist components aims to reduce cholinergic side effects and improve dosing convenience, a challenge noted with earlier muscarinic agents. By targeting specific neural circuits, MapLight Therapeutics hopes to deliver therapies with a better risk benefit profile for patients and prescribers.

MapLight Therapeutics, Inc. intends to serve patients suffering from central nervous system disorders, including schizophrenia, which affects over 20 million people globally and more than three million in the United States; Alzheimer's disease psychosis, which occurs in approximately 40 percent of the roughly seven million individuals living with Alzheimer's disease in the United States; and autism spectrum disorder, which impacts about 1.8 million U. S. children and adolescents and over five million adults. The company anticipates that its future customers will comprise healthcare providers such as psychiatrists and neurologists, hospitals, long term care facilities, and managed care organizations that treat these patient populations. By addressing symptoms not adequately managed by existing therapies, MapLight Therapeutics aims to meet the needs of patients, caregivers, and healthcare systems seeking effective and tolerable treatment options. Successful commercialization would depend on securing formulary coverage and reimbursement from government programs like Medicare and Medicaid and from private health insurers.